MINNEAPOLIS, Sept. 17, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) and QIAGEN N.V. today announced the expansion and extension of a non-exclusive partnership to co-market exosome technology to existing and potential biopharma partners as well as the joint development of new exosome based products. The agreement grants QIAGEN a non-exclusive development license to Bio-Techne’s exosome... Read more
Acquisition of the approval for marketing the Novel Coronavirus (SARS-CoV-2) Detection Reagent Kit as an In Vitro Diagnostic Product Read more
New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers New integrated analyses from our tumour agnostic Rozlytrek® (entrectinib) clinical development programme Blueprint Medicines will present new data from the registrational phase I/II ARROW trial, investigating GavretoTM(pralsetinib) for the treatment of people with RET-mutant medullary... Read more
CANCERPREV Cross-Disciplinary Program Expands Knowledge of Cancer Development to Deliver New Insights into Prevention Strategies Principal Focus on Advancing Understanding of Breast and Skin Cancer Risks SOUTH SAN FRANCISCO, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced its participation in CANCERPREV, a... Read more
Hilden, Germany and Ann Arbor, Michigan, September 17, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248 million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology.... Read more
Wed 16th September 2020 New Cas9 Sequencing Kit provides reagents for one-stop targeted sequencing, enabling scientists to cost-effectively sequence previously inaccessible target regions. Cas9 targeted sequencing with nanopore enables fast, simple, flexible target enrichment of long regions of interest – read lengths of over 100 kb have been observed to date. The approach is amplification-free, opening up regions... Read more
Next-generation biomarker cytology test supports World Health Organization’s goal to eliminate cervical cancer, which is nearly 100 percent preventable with proper screening, vaccination and treatment New indication allows this first FDA-approved biomarker-based test to be used as triage for positive cobas HPV tests run on cobas 6800/8800 Systems in primary screening or co-testing programs More... Read more
Solution helps producers reduce waste, increase product consistency and productivity and lower costs WALTHAM, Mass. – Sept 15, 2020 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today introduced the DA 7350™ instrument and Process Plus™ cloud-based software to provide continuous quality control for food and food ingredient manufacturing processes.... Read more
Thermo Fisher Scientific Further Expands Laboratory Plastics Production to Support COVID-19 Testing, Therapies and Vaccines WALTHAM, Mass. , Sept. 15, 2020 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it is investing more than $140 million to further expand its laboratory plastics consumables production to support significant global demand for... Read more